Surgery – Miscellaneous – Methods
Patent
1998-04-15
2000-06-20
Yu, Micky
Surgery
Miscellaneous
Methods
A61B 1900
Patent
active
060765283
ABSTRACT:
Fructose-1,6-diphosphate (FDP) is used to treat patients who are undergoing coronary artery bypass grafting (CABG) surgery. Before cardiopulmonary bypass begins, a liquid that contains FDP is intravenously infused in the patient, preferably for about 10 to 30 minutes, to allow the FDP to enter the heart and lung tissue while the heart is still beating. FDP can also be added to cardioplegia solution; in addition, FDP can be injected after bypass is terminated, but if post-bypass injection is used, steps should be taken to avoid excess lactic acid accumulation, which appears to increase the risk of atrial fibrillation. To prevent or control lactic acidosis, a buffering or alkalizing agent, such as sodium bicarbonate, or an agent which reduces lactic acid formation, such as dichloroacetate, can be used. In double-blinded trials, this use of FDP substantially reduced heart damage and improved overall outcomes, as shown by lower levels of creatine kinase in blood, improvements in pumping performance, reduced requirements for vasodilator and inotropic drugs, and shorter stays in intensive care units. Certain dosages also reduced the likelihood of atrial fibrillation; however, FDP at high dosages increased the likelihood of A-fib. FDP also helped reduce pulmonary vascular resistance (PVR); this is an important finding, since pulmonary hypertension following cardiopulmonary bypass is a very difficult and often intractable problem, and is a contributing factor in nearly all deaths following CPB surgery.
REFERENCES:
patent: 4546095 (1985-10-01), Markov
patent: 4703040 (1987-10-01), Markov
patent: 4870057 (1989-09-01), Chiapparelli et al.
patent: 5039665 (1991-08-01), Markov
patent: 5506210 (1996-04-01), Parish et al.
patent: 5516526 (1996-05-01), de la Torre
Angelos, M.G., et al, "Fructose-1, 6-diphosphate fails to limit early myocardial infarction size in a canine model," Ann. Emerg. Med. 22: 171-177 (1993).
Benetti, F.J., "Direct coronary surgery with saphenous vein bypass without either cardiopulmonary bypass or cardiac arrest," J. Cardiovasc. Surg. 26: 217-222 (1985).
Brunswick, R., et al., "Preservation of myocardium by infusion of fructose diphosphate following coronary occlusion," abstract, Am J Cardiol 49: 1008 (1982).
Cargnoni, A., et al, "Role of timing of administration in the cardioprotective effect of fructose-1,6-bisphosphate," Cardiovasc Drugs Ther 6: 209-17 (1992).
Conti, V.R., et al, "Metabolic and functional effects of carbohydrate substrate with single-dose and multiple-dose potassium cardioplegia," Ann. Thoracic Surg. 36: 320-327 (1983).
Eddy, L.J., et al, "Lack of a direct metabolic effect of fructose, 1,6-diphosphate in ischemic myocardium," Am J Physiol 241: H576-83 (1995).
"Esafosfina" sales brochure (Biomedica Foscama; Ferentino, Italy).
Farias, L.A., et al, "Effects of fructose-1,6-diphosphate, glucose and saline on cardiac resuscitation," Anesthesiology 65: 595-601 (1986).
Granot, H., et al, "Successful treatment of irreversible hemorrhagic shock in dogs with fructose-1,6 diphosphate and dichloracetate," Circ Shock 163-73 (1985).
Haasinen, I.E., et al, "Mechanism of the effect of exogenous FDP on myocardial energy metabolism," Circulation 83: 584-593 (1991).
Lazzarin G., et al, "Protective effects of exogeneously administered fructose-1,6-diphosphate from ischemia reperfusion damage induced on isolated rat heart," Ital J Biochem 38: 251A-253A (1989).
Lazzarino, G., et al, "Ischemia and reperfusion: effect of fructose-1,6-bisphosphate," Free Radic Res Commun 16: 325-39 (1992).
Marchionni, N., et al, "Hemodynamic and electrocardiographic effects of fructose-1,6-diphosphate in acute myocardial infarction," Am J Cardiol 56: 266-269 (1985).
Markov, A.K., et al, "Prevention of arrhythmias with fructose diphosphate in acute myocardial ischemia," abstract, Circulation 62: III-143 (1980).
Markov, A.K., et al, "Hemodynamic, electrocardiograhic, and metabolic effects of fructose diphosphate on acute myocardial ischemia," Am Heart J 100: 639-46 (1980).
Markov, A.K., "Hemodynamics and metabolic effects of fructose 1-6 diphosphate in ischemia and shock--experimental and clinical observations," Ann Emerg Med 15: 1470-7 (1986).
Markov, A.K., et al, "Increasing survival of dogs subjected to hemorrhagic shock by administration of fructose 1-6 diphosphate," Surgery 102: 515-27 (1987).
Markov, A.K., et al, "Improvement in hemodynamic and pulmonary function following fructose 1-6 diphosphate administration in ARDS patients," Microcirculation 1: 173-178 (1987).
Pasque, M.K., et a, "Metabolic intervention to affect myocardial recovery following ischemia," Annals of Surgery 200: 1-12 (1984).
Sernov, L.N., et al, "The characteristics of the cardioprotective action of fructose-1,6-diphosphate," Biull Eksp Biol Med 111:172-3 (1991) (abstract).
Sernov, L.N., et al, "The antiacidotic and cardioprotective effects of fructose-1,6-diphosphate and dehydroascorbic acid," Farmakol Toksikol 54:24-26 (1991) (abstract).
Sernov, L.N., et al, "A comparative evaluation of the cardioprotective and antianginal actions of energy-providing agents," Eksp Klin Farmakol 55: 13-15 (1992) (abstract).
Stryer, L., Biochemistry, 2nd ed., pp. 266-267 (Freeman & Co., San Francisco, 1981).
Zhang, J.N., et al, "Protective effect of exogenous fructose-1,6-diphosphate in cardiogenic shock," Cardiovasc Res 22: 927-32 (1988).
Fox Anthony W.
Marangos Paul J.
Riedel Bernhard
Royston David
Cypros Pharmaceutical Corp.
Kelly Patrick D.
O'Hara Kelly
Yu Micky
LandOfFree
Injection of fructose-1,6-diphosphate (FDP) prior to coronary ar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injection of fructose-1,6-diphosphate (FDP) prior to coronary ar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injection of fructose-1,6-diphosphate (FDP) prior to coronary ar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1843115